Antiemetics Drugs Market Size, Global Forecast 2034
The Global Antiemetics Drugs Market has witnessed continuous growth in the last few years and is projected to grow even further during the forecast period of 2024-2033. The assessment provides a 360° view and insights - outlining the key outcomes of the Antiemetics Drugs market, current scenario analysis that highlights slowdown aims to provide unique strategies and solutions following and benchmarking key players strategies. In addition, the study helps with competition insights of emerging players in understanding the companies more precisely to make better informed decisions.
📘 Market Introduction
Global size was USD 4.84 billion in 2024, projected to reach USD 8.20 billion by 2031 at a CAGR of 6.8% .
Grand View Research estimates it at USD 7.49 billion in 2023, increasing to USD 11.20 billion by 2030 (CAGR 5.9%) .
Healthcare Insights places the market at USD 7.52 billion in 2022, rising to USD 13.45 billion by 2032 (CAGR ~6.0%) .
Global Growth Insights reports USD 5.21 billion in 2024, growing to USD 7.74 billion by 2033 (CAGR 4.5%) .
🔄 Recent Developments
Jan 2023: Glenmark launched AKYNZEO I.V. in India for chemotherapy-induced nausea .
Mar 2022: Taiho Pharmaceutical introduced Arokaris, a selective NK1 antagonist, for chemotherapy-related symptoms .
Continued approvals and product expansions in the serotonin-receptor antagonist class .
⚙️ Drivers
📈 Rising prevalence of CINV & PONV: chemotherapy side effects (~46% of market), postoperative nausea (~30–80% of surgical patients) .
Growing incidence of gastrointestinal disorders, motion sickness, and pregnancy-related nausea .
Innovations in drug delivery: oral dissolvable films, patches improve compliance .
Expanding geriatric population requiring antiemetic therapies .
Increased R&D and awareness: new formulations, combination therapies, and expanding indications .
🛑 Restraints
Side effects (drowsiness, dizziness) limit usage .
High development costs & regulatory hurdles impede new product launches .
Generic competition pressures pricing .
Variability in patient response and drug interactions complicate standard dosing .
🌱 Opportunities
New therapeutic areas: gastroparesis, viral infections, pediatric nausea .
Personalized medicine guided by pharmacogenomics .
Sustainable drugs/packaging in eco-friendly forms .
Emerging markets (e.g., India grew from USD 337.7 M in 2023 to projected USD 630.7 M by 2030, CAGR 9.3%) .
🚀 Market Advancements
Dominant serotonin-receptor antagonists, with ~29–30% share (~USD 2.23 B in 2023) .
Oral route leads (~USD 4.1 B in 2023), while parenteral routes play strong roles in hospital settings (~USD 3.4 B) .
Chemotherapy remains largest application (~46%), with postoperative segment growing fastest .
Products now include transdermal & dissolvable films, and combination therapies for better outcomes .
🌍 Regional Segmentation Analysis
| Region | 2023–24 Size / Share & Forecast |
|---|---|
| North America | ~36.5–37% share (largest); market led by U.S.; forecast U.S. ~USD 3.42 B by 2030 . |
| Europe | Strong presence; major hospital and pharmacy usage; postoperative growth . |
| Asia‑Pacific | Fastest growth; India USD 337.7 M (2023) to USD 630.7 M (2030, CAGR 9.3%); China also rising . |
| Latin America | Moderate growth; chemotherapy and gastroenteritis drivers . |
| Middle East & Africa | Emerging; driven by improved healthcare access and disease burden . |
✅ Summary
Market size: USD 4.8–7.5 B (2022–24)
Forecast: USD 8.2–13.5 B by 2030–32 (CAGR ~5.9–6.8%)
Drivers: Rising CINV/PONV, R&D, aging, new delivery forms
Challenges: Side effects, cost/regulation, generics, patient variability
Advancements: More effective formulations, personalized dosing, new usage areas
Regional highlights: North America leads; Asia‑Pacific fastest growth; Europe stable; LATAM/MEA emerging
Comments
Post a Comment